for Journals by Title or ISSN
for Articles by Keywords
Followed Journals
Journal you Follow: 0
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.
  Medtech Insight
   Full-text available via subscription Subscription journal
   ISSN (Print) 1876-8008
   Published by Informa plc Homepage  [13 journals]
  • US Heart Valve Treatments Market Fueled By New Transcatheter Valves
    • Abstract: The US heart valve treatments market will reach $1.7 billion by 2019, driven by advances in percutaneous heart valve repair and replacement products and a growing number of competitors entering this space. With US sales of transcatheter aortic valve replacement systems set to almost triple in the next several years, the combined US market for products to treat heart valve disorders is expected to grow at a CAGR of 7.7%.
      PubDate: Fri, 27 Feb 2015 00:05:23 -050
  • Companies Forge Ahead With New Devices, Studies, And Funding For
           Treatment-Resistant Hypertension
    • Abstract: With Medtronic planning to submit an IDE application to the FDA soon to conduct a new US trial of its renal denervation technology, companies and investors alike remain optimistic about finding an effective device-based therapy for treatment-resistant hypertension. Two smaller players in this space – Rox Medical and Verve Medical – are also forging ahead, due to recently published encouraging study results for Rox’s stent-like implant, Coupler, and a nearly $2 million Series B1 round to fund further clinical trials of Verve’s Phoenix RF energy device.
      PubDate: Fri, 27 Feb 2015 00:05:18 -050
  • Alzheimer’s Disease: Moving Toward The Era Of Diagnostic Certainty
    • Abstract: With more than 13 million people in the US expected to have Alzheimer’s disease (AD) by 2050, an increasing number of companies are focused on developing reliable AD diagnostics designed to facilitate early detection and treatment. Although the field remains in its relative infancy, researchers are gaining greater diagnostic certainty through a combination of diagnostic approaches, and over the next decade, the AD diagnostics market is projected to reach a US market value of at least $1 billion to $3 billion per year.
      PubDate: Fri, 27 Feb 2015 00:05:13 -050
  • The Regenerative Market Brings The Future Closer
    • Abstract: A clear sign the regenerative medicine and therapy market is making considerable progress comes from the amount of investor funding pouring into the space, and although a lot of the technology is still spoken about in the future tense, a variety of new companies are bringing the future much closer. An additional hallmark of the market is the role device companies are finding for themselves in an industry primarily lead by pharmaceutical businesses.
      PubDate: Fri, 27 Feb 2015 00:05:00 -050
  • TiaLinx: Developing The First Non-Contact, Non-Ionizing Scanner To Detect
           Breast Cancer
    • Abstract: With the breast cancer screening population expected to reach almost 250 million by 2018, TiaLinx says its new AR60-A scanner is the first non-contact, high-resolution imaging technology that does not emit ionizing radiation, and is an affordable screening alternative for the 210,000 primary care physicians in the US and significantly more worldwide.
      PubDate: Fri, 27 Feb 2015 00:00:11 -050
  • Micro Interventional Devices’ Permaseal Moves
           Closer To Regulatory Approval With Early CE Trial Results
    • Abstract: Preliminary 30-day results from the Secure Transapical Access and Closure Study (STASIS) suggest Micro Interventional Devices’ Permaseal device, a transapical access and closure device for structural heart repair, provides safe and effective hemostasis and wound closure after transapical transcatheter aortic valve replacement. The company estimates the worldwide market potential for the device is more than $3 billion annually.
      PubDate: Fri, 27 Feb 2015 00:00:09 -050
  • Novocure Advances Tumor Treating Fields Technology For Patients With Newly
           Diagnosed Glioblastoma
    • Abstract: Novocure’s tumor treating fields technology offers hope to the 10,000 to 12,000 patients in the US diagnosed with glioblastoma multiforme (GBM), the most common and deadliest form of malignant primary brain tumor. The EF-14 Phase III clinical trial evaluating the company’s Optune device for newly diagnosed GBM was terminated due to early success, and in December 2014, the FDA approved an IDE supplement allowing all control patients in the trial to receive the treatment.
      PubDate: Fri, 27 Feb 2015 00:00:07 -050
  • Medtech Execs On The Move, February 2015
    • Abstract: Recent executive-level company changes and promotions in the medical device and diagnostics industries.
      PubDate: Fri, 27 Feb 2015 00:00:06 -050
  • Medical Device Deals Update, February 2015
    • Abstract: Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced January-February 2015.
      PubDate: Fri, 27 Feb 2015 00:00:03 -050
  • Laurimed: In-Office Removal Of Nasal Polyps
    • Abstract: Laurimed LLC has developed PolypVac, a suction-powered microdebrider for treating nasal polyposis, an inflammatory response to chronic inflammation. It is designed to be used in an ENT’s office in a 15-minute procedure performed under local anesthesia.
      PubDate: Fri, 27 Feb 2015 00:00:02 -050
  • Centerline Biomedical: 3D Navigation For Interventional Vascular
    • Abstract: Centerline Biomedical Inc.’s 3D navigation system for interventional vascular procedures is designed to provide physicians with greater visualization than fluoroscopy,and to reduce caregivers and patients exposure to harmful radiation.
      PubDate: Fri, 27 Feb 2015 00:00:01 -050
  • Spine Market: Making A Comeback
    • Abstract: In spite of increasing price pressure, the $9 billion global spine market is projected to see low-single-digit growth in the next few years. Driving growth are the pure-play spine companies targeting high-growth segments such as minimally invasive surgery, expandable interbody cases, cervical discs, and deformity.
      PubDate: Fri, 30 Jan 2015 00:05:57 -050
  • Active Lifestyles And New Surgical Techniques Driving Sports Medicine
    • Abstract: Although the US sports medicine market is dominated by conservative care treatments, new surgical techniques, arthroscopy products and surgical implants are fueling growth in the market, which is projected to reach almost $15.5 billion by 2018. Industry consolidation and dealmaking among orthopedic manufacturers has yielded several partnerships and M&As that have included a sports medicine element.
      PubDate: Fri, 30 Jan 2015 00:05:50 -050
  • Medtech 2014: M&A, IPOs Bounce Back As Industry Glimpses Future
           Business Models
    • Abstract: Healthy market growth, the biggest ever M&A deal, a record number of billion-dollar takeovers, and the IPO market in impressive bounce-back…2014 was a year of superlatives for the global medtech industry. But with more expected of manufacturers while health care spending remains in the doldrums and demand for care rises, the long-term medtech winners will be those who can forecast how and where to make an impact on both costs and patient outcomes.
      PubDate: Fri, 30 Jan 2015 00:05:12 -050
  • Medtech M&A: Mid-Tiers Poised To Strike In 2015
    • Abstract: This may be the year that mid-sized medtech companies step up their acquisition pace to better compete against larger rivals. To be sure, these players won’t rival Medtronic, Covidien, or the other pre-megamerger partners in size or scope, but they could be in a great position to scoop up smaller companies and technologies in a bid to widen or extend their own pipelines.
      PubDate: Fri, 30 Jan 2015 00:05:01 -050
  • Wearable Ultrasound Probe Enables User To See, Feel, And Do
    • Abstract: Sonivate Medical’s finger-worn ultrasound imaging probe is a ground-breaking solution that is perfectly positioned to satisfy the growing demand for point-of-care diagnostics, as well as "wearable" technology.
      PubDate: Fri, 30 Jan 2015 00:00:11 -050
  • Mouse Avatars: Innovative Approach Holds Promise For Personalizing Cancer
    • Abstract: Champions Oncology has developed TumorGraft, a novel predictive chemo-response technology that allows companies to simulate clinical trials, test anticancer drug regimens, and identify the regimens most likely to positively impact individual cancer tumors. For the clinical trial simulation capabilities alone, the technology has a market potential of $1.6 billion in the US, according to the company.
      PubDate: Fri, 30 Jan 2015 00:00:09 -050
  • Aortica: Customized Fenestrated Endografts
    • Abstract: Aortica Corp. is combining a high-resolution computed tomography scan with proprietary software and 3-D printing technology to create a surgical planning tool for AAA repair. The technology will allow vascular surgeons to make a full-size, patient-specific model aorta to be used as a template to customize a commercially available stent graft before implanting.
      PubDate: Fri, 30 Jan 2015 00:00:08 -050
  • NeuroPrex: TMS For Treating Depression
    • Abstract: NeuroPrex Inc. has developed a transcranial magnetic stimulation device for patients who are unable to take anti-depressants. Its NeuroPrex Classic & Shield is designed to deliver deep, localized energy noninvasively to trigger new synaptic connections and reverse stress-induced neural changes.
      PubDate: Fri, 30 Jan 2015 00:00:07 -050
  • Medtech Execs On The Move, January 2015
    • Abstract: Recent executive-level company changes and promotions in the medical device and diagnostics industries.
      PubDate: Fri, 30 Jan 2015 00:00:06 -050
  • Let The US Drug-Coated Balloon Battle Begin
    • Abstract: Medtronic gained FDA approval for its drug-coated balloon for the peripheral artery, as expected, and it is now gunning to take share from first-to-market CR Bard with the help of impressive clinical data and a formidable Covidien peripheral vascular device sales force.
      PubDate: Fri, 30 Jan 2015 00:00:04 -050
  • HeartFlow Receives Clearance For Noninvasive Testing Of Coronary Artery
    • Abstract: HeartFlow recently gained FDA go-ahead for its FFR-CT technology, a first-of-its-kind, noninvasive diagnostic test that allows physicians to assess blood flow in patients with coronary artery disease. With more than 25 million patients who could potentially benefit from this test in the US, EU, and Japan alone, the market potential for this technology is enormous.
      PubDate: Fri, 30 Jan 2015 00:00:04 -050
  • Medical Device Deals Update, January 2015
    • Abstract: Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Medical Device Deals Update column is a survey of recent medtech M&A, alliance, and financing activity. This month’s column covers deals announced December 2014-January 2015.
      PubDate: Fri, 30 Jan 2015 00:00:01 -050
  • Heart Failure: Next-Gen VADs Fuel Optimism Amid Challenges
    • Abstract: Although near-term challenges have slowed growth in the market for left ventricular assist devices (LVADs), companies are developing new, less invasive VADs with improved pump designs to further improve patient outcomes and allow for a wider application of the therapy in treating heart failure. These next-generation VADs are fueling long-term optimism in the market for mechanical circulatory support, which remains one of the more attractive opportunities in the cardiovascular space.
      PubDate: Tue, 16 Dec 2014 00:05:11 -050
  • Plastic Surgery Market: Fat Grafting Grabs A Hefty Slice Of The Plastics
    • Abstract: Fat, fillers, and a "funnel" that may minimize a common cause of breast implant complications are among the hot topics in both aesthetic and reconstructive plastic surgery. Meanwhile, the acquisition by Actavis of Allergan – a leading player in the aesthetics market with BOTOX and breast implants – has the combined company poised for long-term double-digit revenue and earnings growth.
      PubDate: Tue, 16 Dec 2014 00:05:04 -050
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2014